Longevity Inventory Expands — On Land and At Sea

Four Seasons AMAALA and Six Senses AMAALA have opened simultaneously on Saudi Arabia's Red Sea coast, giving advisors two newly bookable ultra-luxury wellness properties in a single new destination rather than the usual staggered rollout. Six Senses AMAALA anchors its offering around a Longevity Centre and a Biohacking Recovery Lounge; Four Seasons AMAALA counters with longevity diagnostics and regenerative therapies of its own. For clients already loyal to Six Senses or Aman elsewhere, this gives advisors a credible next-destination pitch backed by medically-oriented programming rather than spa-and-pool positioning alone. It's early days commercially — occupancy patterns and package pricing aren't established yet — but the dual-brand debut signals AMAALA is being built deliberately as a longevity hub, not a single-resort bet, which matters when framing it against Amanpuri, Sensei, or Chiva-Som comparisons for prospective bookers.

Amangati, Aman's first ocean-going yacht, has completed float-out in Genoa, and reservations are now open more than a year ahead of its May 2027 Mediterranean maiden season — with an Autumn 2027 Caribbean season since added to the calendar. The 94-guest vessel centers on an 8,000-square-foot Aman Spa plus a dedicated Medi Spa and recovery facilities, effectively porting Aman's land-based longevity positioning onto a yacht-scale format. For advisors, this is a genuinely new category rather than an incremental cruise-spa refresh: early booking windows on a small-capacity, wellness-first yacht tend to sell through top cabin categories first, so clients interested in the category should be flagged now rather than closer to sailing. It sits alongside Seabourn's Dr. Andrew Weil program and Celebrity's spa offerings as another entrant in spa-at-sea, but at a smaller, more exclusive scale.

A new Inspire360 report finds 13.2% of US adults now on GLP-1 medications, and gym operators — Orangetheory, 24 Hour Fitness, NYSC among them — are responding with muscle-preservation programming and telehealth referral partnerships rather than treating the drugs as a threat to membership. The signal for wellness advisors is upstream of any specific supplier: destination spas and longevity retreats should expect a growing share of clients arriving already on GLP-1 therapy, with different recovery, nutrition, and strength-training needs than a pre-GLP-1 retreat cohort. Operators that have already built GLP-1-compatible protocols — muscle-retention circuits, adjusted nutrition programming, medical screening that accounts for the medication — are the ones worth steering these clients toward first, rather than assuming any longevity program is interchangeable. Expect this to show up in program design conversations at destination spas over the next booking cycle.

Onyx CenterSource data shows agency-booked commissionable hotel room nights up 11.8% year-over-year in H1, against roughly 6% growth at both Booking.com and Expedia — agencies growing nearly twice as fast as the OTA channel. Commission-per-night held roughly flat rather than being quietly renegotiated down, meaning the payout growth advisors are seeing is organic volume, not a rate fluke. It's not a wellness-specific data point, but it's a useful one to have on hand when making the case to hotel and retreat partners — including newer longevity properties like AMAALA's — that the advisor channel deserves the same commission terms and allocation attention as direct and OTA business, not an afterthought.